The U.S. Food and Drug Administration have given green signal to glucose-monitoring device for children ages 7 to 17 with type 1 diabetes. Since there are more than 175,000 people suffering from the problem who are less than twenty years of age.
The device, formerly approved only for adults with type-1 diabetes, is called a REAL-Time continuous glucose monitoring (CGM) system, which cautions about dangerously high or low glucose levels, manufacturer Medtronic Inc. of Minneapolis reported.
The company asserted it’s a specifically designed pediatric model of the MiniMed Paradigm REAL-Time System and Guardian REAL-Time System.
Clinical studies showed that REAL-Time continuous glucose monitoring devices help reduce the duration of hypoglycemic events and lower HbA1c levels by as much as 2 percentage points. For every 1 percentage point drop in HbA1c, there is a 35% decline in diabetes-related complications such as blindness, amputation and organ failure.
